Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chaim Gilon

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 27, 2013
Inhibition of inositol monophosphatase (IMPase) at the calbindin-D28k binding site: molecular and behavioral aspectsItzhak Levi, Yael Eskira, Miriam Eisenstein, et al.
Frontiers in Chemistry|December 7, 2020
Cyclizing Painkillers: Development of Backbone-Cyclic TAPS AnalogsAlaa Talhami, Avi Swed, Shmuel Hess, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
RETRACTED: Naamneh et al. Structure-Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities. <i>Pharmaceuticals</i> 2024, <i>17</i>, 549Majdi Saleem Naamneh, Tatjana Momic, Michal Klazas, et al.
Bioorganic & Medicinal Chemistry|July 13, 2010
Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigmMattan Hurevich, Avi Swed, Salim Joubran, et al.
JACS Au|January 3, 2022
Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple SclerosisChaim Gilon, Michal Klazas, Adi Lahiani, et al.
Journal of Molecular and Cellular Cardiology Plus|June 27, 2024
Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in miceAlexandra Njegić, Lina Laid, Min Zi, et al.
Journal of Medicinal Chemistry|January 29, 2008
Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesityShmuel Hess, Yaniv Linde, Oded Ovadia, et al.
Angewandte Chemie (International Ed. in English)|October 27, 2017
Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3Michael Weinmüller, Florian Rechenmacher, Udaya Kiran Marelli, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|April 27, 2013
Inhibition of inositol monophosphatase (IMPase) at the calbindin-D28k binding site: molecular and behavioral aspectsItzhak Levi, Yael Eskira, Miriam Eisenstein, et al.
Frontiers in Chemistry|December 7, 2020
Cyclizing Painkillers: Development of Backbone-Cyclic TAPS AnalogsAlaa Talhami, Avi Swed, Shmuel Hess, et al.
Pharmaceuticals (Basel, Switzerland)|September 27, 2025
RETRACTED: Naamneh et al. Structure-Activity Relationship of Synthetic Linear KTS-Peptides Containing Meta-Aminobenzoic Acid as Antagonists of α1β1 Integrin with Anti-Angiogenic and Melanoma Anti-Tumor Activities. <i>Pharmaceuticals</i> 2024, <i>17</i>, 549Majdi Saleem Naamneh, Tatjana Momic, Michal Klazas, et al.
Bioorganic & Medicinal Chemistry|July 13, 2010
Rational conversion of noncontinuous active region in proteins into a small orally bioavailable macrocyclic drug-like molecule: the HIV-1 CD4:gp120 paradigmMattan Hurevich, Avi Swed, Salim Joubran, et al.
JACS Au|January 3, 2022
Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple SclerosisChaim Gilon, Michal Klazas, Adi Lahiani, et al.
Journal of Molecular and Cellular Cardiology Plus|June 27, 2024
Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in miceAlexandra Njegić, Lina Laid, Min Zi, et al.
Journal of Medicinal Chemistry|January 29, 2008
Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesityShmuel Hess, Yaniv Linde, Oded Ovadia, et al.
Angewandte Chemie (International Ed. in English)|October 27, 2017
Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3Michael Weinmüller, Florian Rechenmacher, Udaya Kiran Marelli, et al.
Pageof 8